Browsing by Author "Kaymakoglu, Sabahattin"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Etiology of Cirrhosis in Turkey: A National Cohort Study
    (2021) Yildirim, Abdullah Emre; Ucbilek, Enver; Oruncu, M. Berk; Turan, Ilker; Demir, Mehmet; Koksal, Aydin; Uyanikoglu, Ahmet; Yilmaz, Nimet; Akarsu, Mesut; Tozlu, Mukaddes; Avcioglu, Ufuk; Haktaniyan, Busra; Aladag, Murat; Yolacan, Ramazan; Toka, Bilal; Kefeli, Ayse; Ormeci, Asli Ciftcibasi; Haciyev, Ferid; Balci, Hatice Rizaoglu; Yurci, Mustafa Alper; Balaban, Hatice Yasemin; Fidan, Sami; Gunduz, Feyza; Gencdal, Genco; Simsek, Cem; Ebik, Berat; Cavus, Bilger; Karatay, Eylem; Sezgin, Gulten Can; Yaras, Serkan; Karabulut, Umit; Gokturk, Huseyin Savas; Uzel, Ali; Ekin, Nazim; Barutcu, Sezgin; Cosar, Arif Mansur; Keklikkiran, Caglayan; Batu, Kerim Deniz; Alkim, Huseyin; Acar, Sencan; Yogun, Yasar; Harputluoglu, Murat; Yalcin, Kendal; Gunsar, Fulya; Sezgin, Orhan; Akarca, Ulus; Kaymakoglu, Sabahattin; Karasu, Abdullah Zeki; Ozdogan, Osman Cavit; Idilman, Ramazan
  • Thumbnail Image
    Item
    Viral hepatitis screening guideline before biological drug use in rheumatic patients
    (2016) Karadag, Omer; Kasifoglu, Timucin; Ozer, Birol; Kaymakoglu, Sabahattin; Kus, Yesim; Inanc, Murat; Keser, Gokhan; Kiraz, Sedat; 27708965
    Biological drugs (tumor necrosis factor inhibitors, rituximab, tocilizumab, abatacept, and tofacitinib) are important treatment alternatives in rheumatology, particularly for resistant patients. However, they may cause hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation; for instance, HBV reactivation may occur in a patient who is an inactive hepatitis B surface antigen (HBsAg) carrier or who has resolved HBV infection. Therefore, the screening of patients before biological treatment and the application of a prophylactic treatment, particularly with respect to latent HBV infections, are recommended when necessary. This guideline covers pre-treatment screening and follow-up recommendations, if required, with respect to viral hepatitides in rheumatology patients who are planned to be given biological drugs. Although this guideline is prepared for biological disease-modifying antirheumatic drugs (DMARDs), it is recommended to be used also for target-oriented DMARDS and medium-high dose corticosteroids (>7.5 mg prednisolone/day equivalent). It should be considered that the reactivation risk is higher when more than one immunosuppressive drug is used.